Latest news

Clinical Update – Debio 025 in Hepatitis C – Debiopharm starts phase IIb triple therapy study, a promising therapeutic avenue

Debiopharm Group et Debio R.P. accueillent Madame la Conseillère fédérale Doris Leuthard sur leur site de Martigny (Valais)

Debiopharm and Aurigene sign licensing agreement for the development and commercialisation of Debio 0617, a novel inhibitor of an undisclosed…

Debiopharm and Pharmaleads sign license agreement for Debio 0827 or PL37 in treatment of chronic pain conditions

Debiopharm announces U.S. NDA filing of Trelstar® 6-month formulation for locally advanced or metastatic prostate cancer

Sanvar® (Debio 8609) for esophageal variceal bleeding – Debiopharm submits response to the FDA

Japanese Cancer Association and Debiopharm Honour Japanese Research – Professors Ichijo and Mano receive 2008 JCA-Mauvernay Award

Clinical Update – Debio 9902 SR (ZT-1) for Alzheimer Patients – Debiopharm Starts Tablet Formulation Bridging Study under IN

Debiopharm moves towards a new 6-month formulation of Decapeptyl® to further help prostate cancer patients